Arcturus Therapeutics Ltd (ARCT) Stock Price, Quote & News

Company Profile

Arcturus Therapeutics Holdings Inc. engages in the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms includes LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate that is in phase 2 clinical trial for...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 900 2660

Website: arcturusrx.com

Address:

10285 Science Center Drive, San Diego, United States

wahoowa96 Feb. 20 at 7:00 PM

$ARCT

0 · Reply

DragonAlgo Feb. 20 at 12:32 PM

🐉 $ARCT CALL — DragonAlgo® Signal Contract: ARCT CALL Expiry: 2026-02-20 | Strike: $7.50 | Type: CALL Option Plan (premium): Entry: $0.57 Stop: $0.41 TP1: $0.74 TP2: $0.97 TP3: $1.37 🔗 https://dragonalgo.com

0 · Reply

Dr_Feel_Good Feb. 20 at 3:06 AM

Thankful for strong performances in $ARCT $IRM $NBIS $CCJ and $EQNR to help steer the portfolio above the flat line going into Friday despite red across the board on the main indexes.

0 · Reply

wahoowa96 Feb. 19 at 8:16 PM

$ARCT any news?

2 · Reply

DragonAlgo Feb. 18 at 8:54 PM

🐉 $ARCT CALL — DragonAlgo® Signal Contract: ARCT CALL Expiry: 2026-03-20 | Strike: $7.50 | Type: CALL Option Plan (premium): Entry: $0.95 Stop: $0.68 TP1: $1.23 TP2: $1.61 TP3: $2.28 Momentum tape remains active. 🔗 https://dragonalgo.com

0 · Reply

bigchouse Feb. 18 at 2:27 PM

$ARCT U.S. FDA reverses course, will review Moderna’s modified flu vaccine application The FDA has accepted Moderna’s revised approach seeking full approval for ‌the shot for adults aged between 50 and 64, and accelerated approval for those aged 65 and above, the company said, adding that it will also conduct a post-marketing study in older adults. Link: https://www.cnbc.com/2026/02/18/us-fda-reverses-course-will-review-modernas-modified-flu-vaccine-application.html

0 · Reply

Newbilly Feb. 18 at 12:56 PM

$ARCT Very

0 · Reply

bigchouse Feb. 18 at 2:15 AM

$ARCT For the latest news, etc. from Arcturus, you can setup email alerts. https://ir.arcturusrx.com/shareholder-services/email-alerts

0 · Reply

bigchouse Feb. 17 at 9:27 PM

$ARCT Arcturus Therapeutics Fourth Quarter and Fiscal Year 2025 Earnings Conference Call Tuesday, March 3, 2026, at 4:30 p.m. ET Domestic: 1-800-274-8461 International: 1-203-518-9814 Conference ID: ARCTURUS Webcast: Link

0 · Reply

bigchouse Feb. 17 at 7:20 PM

$ARCT Balyasny Asset showed up right before the October pump and dump. Now they are Gone Like the Wind. Good.

2 · Reply

Arcturus Therapeutics to Report Fourth Quarter and Fiscal Year 2025 Financial Results and Provide Corporate Update on March 3, 2026

Feb 12, 2026, 2:33 PM EST - 8 days ago

Arcturus Therapeutics: Two Catalysts, One Runway, And A Stock Priced For Failure

Jan 8, 2026, 5:30 PM EST - 6 weeks ago

Arcturus Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Nov 24, 2025, 4:01 PM EST - 3 months ago

Arcturus Therapeutics to Attend Upcoming Investor Conference

Nov 10, 2025, 9:01 PM EST - 3 months ago

Arcturus Therapeutics Holdings Inc. (ARCT) Q3 2025 Earnings Call Transcript

Nov 10, 2025, 4:01 PM EST - 3 months ago

Arcturus Therapeutics Announces Third Quarter 2025 Financial Update and Pipeline Progress

Nov 4, 2025, 4:01 PM EST - 3 months ago

Arcturus Therapeutics to Attend Upcoming Investor Conferences

Oct 28, 2025, 4:01 PM EDT - 4 months ago

Arcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 10, 2025

Oct 22, 2025, 3:05 PM EDT - 4 months ago

Arcturus' Investigational Inhaled Therapy Lacks Meaningful Lung Function Improvement, Analyst Notes Mixed Picture

Oct 22, 2025, 8:53 AM EDT - 4 months ago

Arcturus Therapeutics shares plunge 56% after mixed phase 2 CF drug results

Oct 22, 2025, 7:30 AM EDT - 4 months ago

Arcturus Therapeutics Provides Interim Phase 2 Data for Cystic Fibrosis (CF) Program

Aug 11, 2025, 8:16 PM EDT - 6 months ago

Arcturus Therapeutics Holdings Inc. (ARCT) Q2 2025 Earnings Conference Call Transcript

Aug 11, 2025, 4:01 PM EDT - 6 months ago

Arcturus Therapeutics Announces Second Quarter 2025 Financial Update and Pipeline Progress

Jul 24, 2025, 4:01 PM EDT - 7 months ago

Arcturus Therapeutics to Report Second Quarter Financial Results and Provide Corporate Update on August 11, 2025

Jun 30, 2025, 11:00 AM EDT - 8 months ago

Arcturus Therapeutics Announces Positive Interim Phase 2 Multiple Dose Data for Ornithine Transcarbamylase (OTC) Deficiency Program

Jun 23, 2025, 8:30 AM EDT - 8 months ago

Arcturus Therapeutics to Host Key Opinion Leader (KOL) Presentation of ARCT-810 Phase 2 Interim Data for Ornithine Transcarbamylase (OTC) Deficiency

May 12, 2025, 7:40 PM EDT - 10 months ago

Arcturus Therapeutics Holdings Inc. (ARCT) Q1 2025 Earnings Call Transcript

May 12, 2025, 4:01 PM EDT - 10 months ago

Arcturus Therapeutics Announces First Quarter 2025 Financial Update and Pipeline Progress

Apr 22, 2025, 4:01 PM EDT - 10 months ago

Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 12, 2025

Apr 10, 2025, 8:00 AM EDT - 11 months ago

Arcturus Therapeutics Receives U.S. FDA Fast Track Designation for the STARR® mRNA Vaccine Candidate ARCT-2304 for Pandemic Influenza A Virus H5N1

Mar 6, 2025, 9:44 PM EST - 1 year ago

Arcturus Therapeutics Holdings Inc. (ARCT) Q4 2024 Earnings Call Transcript

Mar 6, 2025, 4:01 PM EST - 1 year ago

Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2024 Financial Update and Pipeline Progress

Mar 5, 2025, 4:30 PM EST - 1 year ago

Arcturus Therapeutics to Present at Leerink's Global Healthcare Conference 2025

Feb 24, 2025, 4:01 PM EST - 1 year ago

Arcturus Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update on March 6, 2025

Feb 14, 2025, 8:30 AM EST - 1 year ago

European Commission Approves CSL and Arcturus Therapeutics' KOSTAIVE®, the First Self-amplifying mRNA COVID-19 Vaccine

Feb 4, 2025, 8:30 AM EST - 1 year ago

Arcturus Therapeutics Announces Appointment of Moncef Slaoui, Ph.D., as Chair Designate

Jan 31, 2025, 3:00 AM EST - 1 year ago

Meiji Seika Pharma Receives Approval for Adding Domestic Manufacturing Sites in Japan for KOSTAIVE®, a Self-amplifying mRNA Vaccine Against COVID-19

Jan 30, 2025, 4:01 PM EST - 1 year ago

Arcturus Therapeutics to Present at Guggenheim Securities SMID Cap Biotech Conference

Jan 10, 2025, 8:00 AM EST - 1 year ago

Arcturus Therapeutics Announces Initiation of Phase 1 H5N1 Flu Vaccine Trial

Jan 6, 2025, 4:01 PM EST - 1 year ago

Arcturus Therapeutics Announces Initiation of Dosing in Phase 2 Multiple Ascending Dose Studies for Cystic Fibrosis (CF) and Ornithine Transcarbamylase (OTC) Deficiency

Dec 16, 2024, 4:01 PM EST - 1 year ago

Arcturus Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Nov 18, 2024, 8:00 PM EST - 1 year ago

Arcturus Therapeutics to Present at Jefferies London Healthcare Conference

Nov 14, 2024, 1:44 PM EST - 1 year ago

Arcturus: LUNAR-CF For CF Presses On With 1st Half Of 2025 Interim Data

Nov 14, 2024, 1:00 AM EST - 1 year ago

Meiji Seika Pharma Announces Investment in ARCALIS, Inc.

Nov 11, 2024, 4:01 PM EST - 1 year ago

Arcturus Therapeutics Receives Clearance from FDA to Begin H5N1 Pandemic Flu Vaccine Clinical Trial

Nov 7, 2024, 11:24 PM EST - 1 year ago

Arcturus Therapeutics Holdings Inc. (ARCT) Q3 2024 Earnings Call Transcript

Nov 7, 2024, 4:01 PM EST - 1 year ago

Arcturus Therapeutics Announces Third Quarter 2024 Financial Update and Pipeline Progress

Oct 31, 2024, 4:01 PM EDT - 1 year ago

Arcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 7, 2024

Sep 30, 2024, 8:00 AM EDT - 1 year ago

Self-Amplifying mRNA COVID-19 Vaccine Demonstrates Superior Immune Response Compared with mRNA Vaccine at 12 Months Post-Vaccination

Sep 13, 2024, 8:15 AM EDT - 1 year ago

Japan's Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics' Updated Self-amplifying mRNA COVID-19 Vaccine for Protection against JN.1 Strain, to be Distributed in Japan by Meiji Seika Pharma

Sep 3, 2024, 8:30 AM EDT - 1 year ago

Arcturus Therapeutics Receives Clearance of an Investigational New Drug Application to U.S. Food and Drug Administration for ARCT-032, an Investigational Inhaled mRNA Therapeutic to Treat Cystic Fibrosis

Aug 27, 2024, 5:00 PM EDT - 1 year ago

Arcturus Therapeutics to Attend Upcoming Investor & Scientific Conferences

Aug 9, 2024, 5:27 AM EDT - 1 year ago

High-Risk, High-Reward: Arcturus Nears Commercialization Of Kostaive Vaccine

Aug 5, 2024, 8:50 PM EDT - 1 year ago

Arcturus Therapeutics Holdings Inc. (ARCT) Q2 2024 Earnings Call Transcript

Aug 5, 2024, 4:01 PM EDT - 1 year ago

Arcturus Therapeutics Announces Second Quarter 2024 Financial Update and Pipeline Progress

Aug 1, 2024, 4:01 PM EDT - 1 year ago

Arcturus Therapeutics to Present at Canaccord Genuity 44th Annual Growth Conference

Jul 18, 2024, 7:30 PM EDT - 1 year ago

Arcturus Therapeutics to Report Second Quarter Financial Results and Provide Corporate Update on August 5, 2024

Jul 1, 2024, 4:01 PM EDT - 1 year ago

Arcturus Therapeutics Provides Updates for Ornithine Transcarbamylase (OTC) Deficiency and Cystic Fibrosis (CF) Programs

Jun 20, 2024, 8:00 AM EDT - 1 year ago

Arcturus Therapeutics Appoints Moncef Slaoui, Ph.D., to Board of Directors

wahoowa96 Feb. 20 at 7:00 PM

$ARCT

0 · Reply

DragonAlgo Feb. 20 at 12:32 PM

0 · Reply

Dr_Feel_Good Feb. 20 at 3:06 AM

Thankful for strong performances in $ARCT $IRM $NBIS $CCJ and $EQNR to help steer the portfolio above the flat line going into Friday despite red across the board on the main indexes.

0 · Reply

wahoowa96 Feb. 19 at 8:16 PM

$ARCT any news?

2 · Reply

DragonAlgo Feb. 18 at 8:54 PM

0 · Reply

bigchouse Feb. 18 at 2:27 PM

0 · Reply

Newbilly Feb. 18 at 12:56 PM

$ARCT Very

0 · Reply

bigchouse Feb. 18 at 2:15 AM

$ARCT For the latest news, etc. from Arcturus, you can setup email alerts. https://ir.arcturusrx.com/shareholder-services/email-alerts

0 · Reply

bigchouse Feb. 17 at 9:27 PM

0 · Reply

bigchouse Feb. 17 at 7:20 PM

$ARCT Balyasny Asset showed up right before the October pump and dump. Now they are Gone Like the Wind. Good.

2 · Reply

EnigmaticFan Feb. 17 at 7:02 PM

$ARCT CSL recognized an impairment write down of $1.1 Billion in regards to their mRNA franchise. It looks like they have abandoned or rolled in their own wholly owned candidates into the Arcturus collaboration. Could have some interesting things on the way in this partnership. We’ve had limited information regarding their collaboration on flu and RSV, but once they got some initial data they canceled their own programs. Could be something there we can read between the lines.

3 · Reply

wahoowa95 Feb. 17 at 2:45 AM

$ARCT i wonder what CEO payne is cooking up with CSL

1 · Reply

_MihawkSwings Feb. 16 at 9:25 PM

The chart on OLB is looking very explosive. No wonder folks are talking about it everywhere. OLB has the look and and the recipe to see a 200-300%+ move. With pennies being the theme currently, OLB fits in perfectly, plus 0 borrow/low float and upcoming catalyst. $CMPS $GSAT $ARCT $OMAB watching.

0 · Reply

WallStreetBuyDip Feb. 16 at 8:22 PM

Comparing trending tickers $ARCT vs $AKAM: ARCT has edged up slightly today, by 0.56% to $7.21, with trading volume at 318.6K, which is below its average of 704.8K. In contrast, AKAM has surged by 6.83% to $111.76 on a much higher volume of 7.3M shares, significantly exceeding its average of 2.7M. This shows AKAM experiencing a notable price jump accompanied by a substantial increase in trading activity, while ARCT's smaller gain comes with less trading activity relative to its usual volume.

0 · Reply

WallStreetBuyDip Feb. 16 at 8:08 PM

Comparing trending tickers $GRAL vs $ARCT: GRAL rose to $97.50, marking a 1.68% increase on a volume of 450.4K shares, which is below its average of 1.2M. Meanwhile, ARCT modestly climbed 0.56% to $7.21 with a trading volume of 318.6K shares, also under its usual 704.8K. While both stocks are up today, GRAL's price increase is more substantial despite both trading below their average volumes.

0 · Reply

mikesterz7 Feb. 16 at 7:05 PM

$ARCT The company plans to initiate a 12-week safety and preliminary efficacy study in up to 20 cystic fibrosis participants in the first half of 2026.

1 · Reply

UgoGreg Feb. 16 at 6:58 PM

$ARCT https://youtu.be/ygBN8MilTyc

0 · Reply

UgoGreg Feb. 16 at 6:48 PM

$ARCT https://youtu.be/ygBN8MilTyc

0 · Reply

wahoowa96 Feb. 13 at 3:57 PM

$ARCT "If proven effective, Enteromix could reduce reliance on long-term, expensive drug therapies, potentially providing a cost-effective alternative for millions of patients..."

1 · Reply

wahoowa96 Feb. 13 at 3:54 PM

$ARCT Russia and China are about to secure IP on personalized cancer vaccines first. https://thedailycpec.com/china-may-approve-russian-cancer-vaccine-enteromix/

2 · Reply

wahoowa96 Feb. 13 at 4:49 AM

$ARCT If you want to cheat the system start phase 3 in August and stop around May... That's Vertex playbook.

2 · Reply

wahoowa96 Feb. 13 at 4:45 AM

$ARCT in the fireplace chat ceo Joseph Payne mentioned hot humid summer weather contributed to the FEV1 fluctuations. 12 weeks study in April through June is good time. I saw extreme summer weather introduce 4 % decrease in FEV1 per 14 F increase in temperature which can happen by staying outside vs staying indoors.

0 · Reply

Market Cap	226.46M
Revenue (ttm)	152.31M
Net Income (ttm)	-80.94M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-53.14%
Debt to Equity Ratio	0.00

Volume	409,600
Avg Vol	527,524
Day's Range	N/A - N/A
Shares Out	28.41M
Stochastic %K	65%
Beta	2.39
Analysts	Strong Sell
Price Target	$29.25